Sino Biopharmaceutical

A chessboard with blocks that read MA
Biotech

Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova

LaNova's PD-1xVEGF bispecific antibody was licensed to Merck in a $588 million upfront deal.
Angus Liu Jul 15, 2025 10:16am
shooting star over mountain at night

F-star breaks free from invoX after $161M acquisition

Apr 4, 2025 10:03am
Photo of three hands placing together three white puzzle pieces

Takeda adds F-Star collab to constellation worth up to $1B

Jul 5, 2023 2:00pm